November 7, 2016
Celyad's NKR phase I trial shows encouraging results
The first data analysis of the NKR-2 Phase I trial, run by the Belgia’s biopharmaceutical company Celyad, shows encouraging results
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Frédéric Lehmann
December 1, 2015
Celyad advances first NKG2D CAR T-Cell Phase I study
Celyad advances first NKG2D CAR T-Cell Phase I study